MolecuLight Inc. Ontario

is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.

For sales, media or other inquiries or further information, please contact
Danielle Dunham
Director of Product
MolecuLight Inc.
T. +1.416.542.5524
ddunham@moleculight.com
www.moleculight.com

Photo - https://mma.prnewswire.com/media/2657051/MolecuLight_Study_Links_Bacterial_Load_to_Pain_in_Venous_Ulcers_.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/study-links-bacterial-load-to-pain-in-venous-ulcers-demonstrating-effective-reduction-with-moleculight-302419148.html